EIF4EBP2: A Potential Drug Target and Biomarker (G1979)

Target Name: EIF4EBP2

NCBI ID: G1979

EIF4EBP2

EIF4EBP2: A Potential Drug Target and Biomarker

EIF4EBP2 (endoplasmic reticulum-associated protein 2) is a protein that is expressed in various tissues and cells in the human body. It is a member of the endoplasmic reticulum-associated protein (ERP) family, which includes a variety of transmembrane and cytoplasmic proteins that play important roles in cellular signaling and organization. One of the unique features of EIF4EBP2 is its ability to interact with various signaling molecules, including kinases and phosphatidylinositol (PI) molecules. This interaction between EIF4EBP2 and PI molecules makes it a potential drug target and biomarker for a variety of diseases.

Diseases and Their Potential Interactions with EIF4EBP2

EIF4EBP2 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in these diseases has led to the search for new treatments and drug targets. One of the promising areas of research is the use of small molecules, such as drugs that can modulate the activity of EIF4EBP2, as potential disease treatments.

One of the most promising potential drug targets for EIF4EBP2 is the PI3K/Akt signaling pathway, which is involved in many cellular processes, including cell signaling, survival, and angiogenesis. The PI3K/Akt signaling pathway is a target for many drugs that are currently being used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. By targeting EIF4EBP2, drugs can modulate the activity of this protein and potentially inhibit the signaling pathway, leading to a variety of potential therapeutic effects.

Another potential drug target for EIF4EBP2 is the T-cell signaling pathway, which is involved in many cellular processes, including immune surveillance and regulation. The T-cell signaling pathway is a critical aspect of immune function, and drugs that can modulate the activity of EIF4EBP2 have been shown to have potential therapeutic effects in a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

EIF4EBP2 as a Biomarker

In addition to its potential as a drug target, EIF4EBP2 has also been shown to be a valuable biomarker for a variety of diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that EIF4EBP2 may be a useful biomarker for these diseases, and that its levels can be used as a diagnostic tool.

One of the key advantages of EIF4EBP2 as a biomarker is its stability and its ability to be used in a variety of detection techniques, including Western blotting, immunofluorescence, and mass spectrometry. This makes it a valuable tool for the detection and quantification of EIF4EBP2 in a variety of biological samples, including blood, urine, and tissue samples.

In addition to its use as a biomarker, EIF4EBP2 has also been shown to be involved in the regulation of cellular processes, including cell signaling and the production of extracellular vesicles (EVs). These EVs can be involved in a variety of cellular processes, including cell adhesion, migration, and survival. The regulation of EV production by EIF4EBP2 is an area of ongoing research, and its potential implications for cellular processes and diseases may be significant.

Conclusion

EIF4EBP2 is a protein that has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its interaction with signaling molecules, including PI molecules and T-cell signaling pathway, makes it a potential drug target and biomarker for a variety of diseases. The use of small molecules, such as drugs that can modulate the activity of EIF4EBP2, may lead to new therapeutic options for the treatment of these diseases. Further research is needed to fully understand the role of EIF4EBP2 in disease and to develop new treatments based on its potential as a drug target and biomarker.

Protein Name: Eukaryotic Translation Initiation Factor 4E Binding Protein 2

Functions: Repressor of translation initiation involved in synaptic plasticity, learning and memory formation (PubMed:30765518). Regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form of EIF4EBP2 competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repress translation. In contrast, hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation (PubMed:30765518, PubMed:25533957). EIF4EBP2 is enriched in brain and acts as a regulator of synapse activity and neuronal stem cell renewal via its ability to repress translation initiation (By similarity). Mediates the regulation of protein translation by hormones, growth factors and other stimuli that signal through the MAP kinase and mTORC1 pathways (By similarity)

The "EIF4EBP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4EBP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets